Latest Breaking News On - Board member of cancer pain research consortium - Page 1 : vimarsana.com

Ketamir-2, the Company s novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression MIAMI, May 21, 2024.

United statesErez aminovAmitabh gulatiItzchak angelSloan ketteringPharmaceuticals incSecurities exchangeBoard member of cancer pain research consortiumNational cancer instituteSloan kettering cancer centerPharmaceuticals in discussionsDrug administrationPharmaseed ltdSloan kettering instituteMemorial sloan kettering cancer centerUs drug enforcement administration